The FDA has granted Fast Track Designation to Adicet Bio’s ADI-001, an allogeneic gamma delta CAR T-cell therapy, for ...

Adicet Bio (ACET) announced the FDA has granted fast track designation to ADI-001 for the potential treatment of adult patients with refractory ...

Adicet Bio, Inc. (ACET), a clinical stage biotechnology company, Wednesday said it received Fast Track Designation from the U.S. Food ...

NextLoopp Americas aims to mobilize U.S.-based organizations to participate in closing the loop on the most prolific fraction ...

The doctors group is seeking to restore websites and data taken down by the Centers for Disease Control and Prevention, Food ...

PRINCETON - PDS Biotechnology Corporation (NASDAQ:PDSB) has confirmed plans to commence its VERSATILE-003 Phase 3 clinical trial for a promising cancer immunotherapy within the first quarter of 2025.

Philadelphia-based Independence Blue Cross has set a benefit exclusion for products that receive accelerated approval from ...

Acrivon Therapeutics, Inc. (NASDAQ: ACRV), a clinical stage biopharmaceutical company with a market capitalization of $184 million and an impressive 60% stock return over the past year, announced that ...

Stay up-to-date with the latest and best audio content from CBC Listen delivered to your inbox every two weeks.